Royalty Pharma (MEX:RPRXN) ROE % Adjusted to Book Value: 6.37% (As of Mar. 2026)


MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
72 GF Score
Price MXN775.06
GF Value MXN535.17
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma ROE % Adjusted to Book Value?

Royalty Pharma MEX:RPRXN 72 ROE % Adjusted to Book Value is 6.37% as of Mar. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review.

Royalty Pharma's ROE % for the quarter that ended in Mar. 2026 was 17.65%. Royalty Pharma's PB Ratio for the quarter that ended in Mar. 2026 was 2.77. Royalty Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 6.37%.

Royalty Pharma ROE % Adjusted to Book Value Related Terms

Royalty Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma ROE % Adjusted to Book Value Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only 3.90 0.21 9.19 8.60 4.10

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.56 0.76 7.19 5.08 6.37

MEX:RPRXN vs BNTX, INSM, ROIV: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Royalty Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Royalty Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's ROE % Adjusted to Book Value falls into.


MEX:RPRXN
72GF Score
Royalty Pharma PLC MEX:RPRXN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma ROE % Adjusted to Book Value Calculation

Royalty Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.62% / 2.59
=4.10%

Royalty Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=17.65% / 2.77
=6.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 6.37% mean?
Royalty Pharma (MEX:RPRXN) has a ROE % Adjusted to Book Value of 6.37% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's ROE % Adjusted to Book Value too high?
Royalty Pharma's current ROE % Adjusted to Book Value is 6.37%. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's ROE % Adjusted to Book Value compare to BNTX and INSM?
Royalty Pharma's ROE % Adjusted to Book Value of 6.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current ROE % Adjusted to Book Value is 6.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current ROE % Adjusted to Book Value of 6.37%. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 6.37%. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current ROE % Adjusted to Book Value is 6.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.

Key valuation signals for MEX:RPRXN:

  • ROE % Adjusted to Book Value: 6.37%
  • GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for MEX:RPRXN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN775.06
Price
MXN535.17
GF Value